Previous observational studies on patients with T2DM and ASCVD demonstrate that the administration rates of GLP-1 RA and/or SGLT2i ranged from 6.7% to 23.2%, ACEI or ARB was from 53.1% to 72.0%, and high-intensity statins were from 24.7% to 45.4% (18–21). The gene discussed is GLP1R; the disease is atherosclerosis.